MedTrace Logo

Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis

NCT00823173 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2011-05-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether ESBA105, a topically applied TNF-alpha inhibitor, is safe and clinically active when applied to the eye of patients suffering from acute anterior uveitis

Conditions

  • Anterior Uveitis

Interventions

BIOLOGICAL

ESBA105

ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)

Sponsors & Collaborators

  • ESBATech AG

    lead INDUSTRY

Principal Investigators

  • Manfred Zierhut, MD · Universitäts-Augenklinik Tübingen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00823173 on ClinicalTrials.gov